Kidney Week

Abstract: FR-PO224

SGLT2 Inhibitor Use and Kidney Outcomes in Persons Receiving Cisplatin

Session Information

• Onconephrology: Immunotherapy Nephrotoxicity and Assessment of GFR
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Onconephrology

• 1700 Onconephrology

Authors

• Idowu, Abiodun Benjamin, Jefferson Einstein Philadelphia Hospital, Philadelphia, Pennsylvania, United States

Abiodun Benjamin Idowu, MD

• Lo, Kevin Bryan, Brigham and Women's Hospital Division of Cardiovascular Medicine, Boston, Massachusetts, United States

Kevin Bryan Lo, MD

• Mathew, Roy O., Loma Linda University, Loma Linda, California, United States

Roy O. Mathew, MD, FASN

• Garimella, Pranav S., University of California San Diego Division of Nephrology-Hypertension, La Jolla, California, United States

Pranav S. Garimella, MD, MPH, FASN

• Rangaswami, Janani, Division of Nephrology, Veterans Affairs Medical Center,, Washington, District of Columbia, United States

Janani Rangaswami, MD

Background

SGLT2i are protective against progressive kidney function loss, yet their role in preventing drug toxicity is unknown. We sought to determine safety of concurrent SGLT2i use with cisplatin, a chemotherapy with significant nephrotoxicity

Methods

A Retrospective analysis of patients ages 18–65 years treated with cisplatin from 1^st January 2000 to 31^st May 2023 in TriNetX database. Patients were divided into 2 groups based on SGLT2i use (first-time exposure to SGLT2i within 3 months before or up to 3 months after first cisplatin administration). Cohorts were balanced via nearest-neighbor 1:1 propensity-score matching (PSM). Survival analysis was done via Kaplan-Meier curves with log-rank tests over a 1-year follow-up

Results

After PSM, we identified 150 patients per cohort (Fig 1). At 1 year, there was a significant decline of eGFR by 17.1+4.16 mL/min/1.73m² in the SGLT2i group and 16.3+3.61 mL/min/1.73m² in the non-SGLT2i group. There were fewer MAKE event rates, as well as its components (AKI, RRT, and mortality) in the SGLT2i group vs non SGLT2i, but the differences were not statistically significant (HR 0.88, 95%CI: 0.58-1.34, p=0.553) (Fig 2)

Conclusion

SGLT2i use during cisplatin therapy was not associated with increased AKI or MAKE risk. Prospective studies are needed to assess the nephroprotective potential of SGLT2i while on cisplatin therapy

Patient characteristics

Kidney Outcomes of concurrent SGLT2i and Cisplatin use